Poseida Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Poseida Therapeutics, Inc.
Public Company Edition: Sage will reveal cost reductions later in the third quarter after the US FDA approved zuranolone for the smaller of two depression indications. Also, Karyopharm revealed a 20% workforce reduction, Harmony accessed up to $185m in debt and Astellas invested $50m in Poseida.
More BCMA-directed therapies are in development, as well as ones targeting GPRC5D and FcRH5, along with CELMoDs. The question is how to bring those into therapy and pay for them.
The major Japanese firm says decision prompted by desire to focus more resources on late-stage clinical candidates and core therapeutic areas, while expanding deals.
Neuroscience and oncology fuel high hopes for therapeutic R&D progress among 90-plus surveyed biopharma industry leaders.
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Gene Therapy, Cell Therapy
- Nanotechnology, Chips, etc.
Drug Discovery Tools
- Other Names / Subsidiaries
- Transposagen Biopharmaceuticals, Inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.